Brief: Cyclacel Pharmaceuticals Achieves Key Business Objectives In First Half Of 2022 And Continues To Advance Clinical Pipeline

Bio Green Med Solution

30/06/2022 14:17

June 30 (Reuters) - Cyclacel Pharmaceuticals Inc  CYCC.O :
    * CYCLACEL PHARMACEUTICALS ACHIEVES KEY BUSINESS OBJECTIVES
IN
FIRST HALF OF 2022 AND CONTINUES TO ADVANCE CLINICAL PIPELINE
    * CYCLACEL PHARMACEUTICALS INC - NO DOSE LIMITING TOXICITIES
OBSERVED AT ALL DOSE LEVELS ENROLLED TO DATE
    * CYCLACEL PHARMACEUTICALS INC - DEMONSTRATED EVIDENCE OF
TARGET
ENGAGEMENT FOR CDK2 AND CDK9
    * CYCLACEL PHARMACEUTICALS INC - COMPLETED ENROLLMENT IN
PHASE 1
DOSE ESCALATION WITH ORAL FADRACICLIB IN SOLID TUMORS

Source text for Eikon:  ID:nGNX6SyjTP 
Further company coverage:  CYCC.O